Paclitaxel trevatide

Drug Profile

Paclitaxel trevatide

Alternative Names: ANG-1005; AngioPep1; GRN-1005; Paclitaxel peptide vector conjugate - Angiochem

Latest Information Update: 06 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AngioChem
  • Class Antineoplastics; Drug conjugates; Paclitaxels; Peptides
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Brain metastases; Glioblastoma; Glioma

Most Recent Events

  • 08 Dec 2016 Paclitaxel trevatide is still in phase II trials for Glioblastoma in USA (IV)
  • 06 Dec 2016 Additional efficacy data from a phase II trial in Breast cancer presented at the 39th Annual San Antonio Breast Cancer Symposium (SABCS-2016)
  • 07 Oct 2016 Efficacy data from a phase II trial in Brain metastases (from breast cancer) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top